How does angiotensin II increase cardiac dopamine-beta-hydroxylation?
The potent accelerating effect of angiotensin II (Ang II) on caridac dopamine beta-hydroxylation was studied on slices of rat heart. Ang II did not affect the kinetics of beta-hydroxylation but it increased the axonal uptake of dopamine, and, concomitant with the acceleration of biosynthesis, it enhanced the accumulation of dopamine into tissue. Puromycin, in contrast to actinomycin D, antagonized the stimulation of dopamine beta-hydroxylation by Ang II, but did not suppress the rise in cardiac dopamine. Therefore, to promote the acceleration of dopamine beta-hydroxylation, (i) the rise in tissue dopamine available for conversion appeared to be insufficient, (ii) the formation of new proteins by activation of traduction seemed to constitute the basic mechanism of Ang II action.
D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D003609:Dactinomycin / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D006352:Heart Ventricles / Q000201:enzymology; D066298:In Vitro Techniques; D007700:Kinetics; D009124:Muscle Proteins / Q000096:biosynthesis; D009206:Myocardium / Q000201:enzymology*; D009655:Octopamine / Q000494:pharmacology; D011691:Puromycin / Q000494:pharmacology; D051381:Rats; D013268:Stimulation, Chemical
D009124:Muscle Proteins; D000804:Angiotensin II; D009655:Octopamine; D003609:Dactinomycin; D011691:Puromycin; D004299:Dopamine beta-Hydroxylase; D004298:Dopamine